Ph I/II study of oral selective AXL inhibitor bemcentinib (BGB324) in combination with erlotinib in patients with advanced EGFRm NSCLC: End of trial update.Lauren Averett Byers,Kathryn A. Gold, Julio Antonio Peguero,Melissa Lynne Johnson,Jorge J. Nieva, Wael A. Harb,Alberto Chiappori,Igor I. Rybkin, James Fredric Strauss,David E. GerberJOURNAL OF CLINICAL ONCOLOGY（2021）引用 9|浏览6暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
